title: [Pilot study and preliminary validation of the French version of a quality-of-life questionnaire specific for subjects with growth hormone deficiency].
abstract: This study forms part of a research project seeking to develop a standardized questionnaire by which clinicians can assess the impact of growth hormone (GH) deficiency and its treatment on the "perceived health" or health-related quality of life of adults. The specific aim of this study was to translate and adapt for French patients the AGHDA (Adult Growth Hormone Deficiency Assessment) a standardized health-related quality of life measure for use with GH-deficient adults, initially developed in the United Kingdom, and to collect data which could be used to assess the main psychometric characteristics of its French version the ISPA-HC (Indicateur de Santé Perceptuelle Adulte-Hormone de Croissance). The main properties analyzed are: 1/ The scale's acceptability, as determined by means of face-to-face interviews with a small number of subjects, then by an ad hoc questionnaire administered during a test-retest study; 2/ The scale's reliability, as determined by a test-retest study (with a 15-days interval between tests); 3/ The scale's concurrent validity, as expressed by comparison with scores obtained by means of a generic quality of life scale, the ISPN (the French version of the Nottingham Health Profile). The results of this first trial with the ISPA-HC are conforming to what one can expect from a good instrument. The ISPA-HC has been shown to have very good levels of reliability and internal consistency. Its scores show a close correlation with those of the ISPN (the French version of the Nottingham Health Profile). This instrument can be used to measure variations in the perceived health of subjects with growth hormone deficiency. Its responsiveness to change is to be examined in subsequent studies.
authors.affiliation: EA 2494, UFR Cochin-Port Royal, Université Paris V, 27 rue du Faubourg Saint Jacques, F-75014 Paris. leplege@vjf.inserm.fr
authors.forename: A
authors.initials: A
authors.lastname: Leplège
authors.forename: E
authors.initials: E
authors.lastname: Ecosse
authors.forename: F
authors.initials: F
authors.lastname: Archambau
authors.forename: S
authors.initials: S
authors.lastname: Arlot
authors.forename: I
authors.initials: I
authors.lastname: Bachelot
authors.forename: J-P
authors.initials: JP
authors.lastname: Bercovici
authors.forename: P
authors.initials: P
authors.lastname: Bouchard
authors.forename: M
authors.initials: M
authors.lastname: Colle
authors.forename: D
authors.initials: D
authors.lastname: Dewailly
authors.forename: P
authors.initials: P
authors.lastname: Hassler
authors.forename: Y
authors.initials: Y
authors.lastname: Lorcy
authors.forename: J-P
authors.initials: JP
authors.lastname: Luton
authors.forename: P
authors.initials: P
authors.lastname: Roger
authors.forename: P
authors.initials: P
authors.lastname: Valensi
authors.forename: G
authors.initials: G
authors.lastname: Schaison
mesh_terms: D000328:Adult; D005602:France; D006304:Health Status; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use; D006801:Humans; D010865:Pilot Projects; D011788:Quality of Life; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires
chemical_list: D019382:Human Growth Hormone